Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MTTP | P55157 | 8/20 | 0.42 |
| ▸ | APOB | P04114 | 4/20 | 0.42 |
| ▸ | ADAMTS7 | Q9UKP4 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646726 | 0.86 | PTGS1 (0.46) | GAASMN1; SMN2KDM4ESMOALDH1A1 | |
| SCHEMBL6647807 | 0.82 | MTTP (0.42) | GAASMN1; SMN2KDM4ESMOMTTP | |
| SCHEMBL6647724 | 0.81 | THRB (0.48) | GAASMOALDH1A1LMNAMTTP | |
| SCHEMBL6644462 | 0.79 | GAA (0.47) | GAASMN1; SMN2KDM4ESMOALDH1A1 | |
| SCHEMBL6795331 | 0.78 | SMO (0.43) | GAASMN1; SMN2KDM4ESMOMTTP | |
| SCHEMBL6793327 | 0.76 | SMO (0.59) | GAASMOALDH1A1LMNAMTTP | |
| SCHEMBL6647101 | 0.76 | PTGS1 (0.46) | GAASMN1; SMN2SMOMTTPAPOB | |
| SCHEMBL6642272 | 0.75 | SMO (0.43) | GAASMN1; SMN2KDM4ESMOALDH1A1 | |
| SCHEMBL6915464 | 0.74 | GAA (0.56) | GAASMN1; SMN2MTTPAPOBKMT2A | |
| SCHEMBL6793055 | 0.74 | SMO (0.49) | GAASMOLMNAMAPTMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | GAA 3155/4885SMN1; SMN2 1836/4885KDM4E 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.